过去一年中添加的文章，按日期排序
Impact of different dose reduction criteria on dose assignment of current DOACs and related outcomes: an analysis from 4-year data of the ETNA-AF Europe …
I Diemberger, R Schnabel, P Ameri, EM Fronk… - Europace, 2024 - academic.oup.com
23 天前 - … in the ETNA population was highly heterogenous across different DOACS: 5.7% for
apixaban, 16.8% for rivaroxaban, 23.8% for edoxaban and 52.9% for dabigatran. Moreover, …
apixaban, 16.8% for rivaroxaban, 23.8% for edoxaban and 52.9% for dabigatran. Moreover, …
[HTML][HTML] Effectiveness and safety in non-valvular atrial fibrillation patients switching from warfarin to direct oral anticoagulants in US healthcare claims
GYH Lip, V Noxon, A Kang, X Luo, N Atreja… - Journal of Thrombosis …, 2024 - Springer
44 天前 - … There is a paucity of real-world studies examining the risks of stroke/systemic embolism
(SE… from warfarin to apixaban, dabigatran, or rivaroxaban in real-world clinical practice. …
(SE… from warfarin to apixaban, dabigatran, or rivaroxaban in real-world clinical practice. …
[HTML][HTML] Balancing the Risks of Stroke and Bleeding in Patients With Atrial Fibrillation and Renal Dysfunction
P Shivamurthy, DS Frankel - JACC: Advances, 2024 - jacc.org
100 天前 - … clearance: dabigatran 80%… safety in mild to moderate CKD (15-60 ml/min). Another
study found that Edoxaban 30 mg had the most favorable safety profile, and only dabigatran …
study found that Edoxaban 30 mg had the most favorable safety profile, and only dabigatran …
[PDF][PDF] Reperfusion therapy of ischaemic strokes in oral anticoagulated patients: an expanding field in clinical practice
B Karaszewski - Neurologia i Neurochirurgia Polska, 2023 - journals.viamedica.pl
179 天前 - … Real-life experience with the specific reversal agent idarucizumab for the management
of emergency situations in dabigatran-treated patients: a series of 11 cases. J Thromb …
of emergency situations in dabigatran-treated patients: a series of 11 cases. J Thromb …
The search for the perfect antiplatelet treatment continues
S Agewall - European Heart Journal-Cardiovascular …, 2023 - academic.oup.com
185 天前 - … and safety for very low dose (VLD) non-vitamin K antagonist oral anticoagulants
(NOACs) [edoxaban 15 mg od, dabigatran … a real-world cohort of elderly atrial fibrillation (AF) …
(NOACs) [edoxaban 15 mg od, dabigatran … a real-world cohort of elderly atrial fibrillation (AF) …
Clinical outcomes in elderly atrial fibrillation patients at increased bleeding risk treated with very low dose vs. regular-dose non-vitamin K antagonist oral …
YH Chan, TF Chao, SW Chen, HF Lee… - European Heart …, 2023 - academic.oup.com
306 天前 - … and safety for VLD non-vitamin K antagonist oral anticoagulants (NOACs) [edoxaban
15 mg od, dabigatran … NOACs) among a real-world cohort of elderly atrial fibrillation (AF) …
15 mg od, dabigatran … NOACs) among a real-world cohort of elderly atrial fibrillation (AF) …
[HTML][HTML] PB2191: A RETROSPECTIVE MULTI-CENTER STUDY ON DIRECT ORAL ANTICOAGULANT USE IN BCR:: ABL1 NEGATIVE MYELOPROLIFERATIVE …
M Baysal, P Patir, V Gursoy, R Çiftçiler, U Demirci… - …, 2023 - journals.lww.com
320 天前 - … We assessed the efficacy and safety of DOACs. Regarding safety, we documented
the … (6.7%) patients are on edoxaban and dabigatran, respectively. A total of seven bleeding …
the … (6.7%) patients are on edoxaban and dabigatran, respectively. A total of seven bleeding …